Hay Fever
Also known as: Pollen allergy
Methodology & AI Transparency ⓘ
Hay Fever Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Each spring, summer, and fall, trees, weeds, and grasses release tiny pollen grains into the air.
- 2 Real-world patient consensus: Synonyms for Hay Fever (J32.7): Pollen allergy (Allergies & Sinus).
- 3 Typical cash cost range: Clinicians assessing Hay Fever focus on IgE-crosslinked mast-cell [Hay Fever J32.7] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Hay Fever: Serum Total IgE in Hay Fever (J32.7: & Tryptase (if) (Tryptase < 11.4 ng/mL (J32.7)) and Specific IgE Allergen in Hay Fever (J32.7: Panel / Skin).
Ask our AI Specialists anything about Hay Fever
What Is Hay Fever?
Each spring, summer, and fall, trees, weeds, and grasses release tiny pollen grains into the air. Some of the pollen ends up in your nose and throat. This can trigger a type of allergy called hay fever. Symptoms can include: Sneezing, often with a runny or clogged nose Coughing and postnasal drip Itching eyes, nose and throat Red and watery eyes Dark circles under the eyes Your health care provider may diagnose hay fever based on a physical exam and your symptoms. Sometimes skin or blood tests are used. Taking medicines and using nasal sprays can relieve symptoms. You can also rinse out your nose, but be sure to use distilled or sterilized water with saline.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Hay Fever (ICD-10 J32.7) is driven by IgE-crosslinked mast-cell [Hay Fever J32.7]; Cross-referenced with NIH MeSH (Rhinitis, Allergic, Seasonal), specialists in Allergies, Sinusitis & Immune Reactions monitor Specific IgE Allergen in Hay Fever (J32.7: Panel / Skin) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Sneezing, often with a runny or clogged nose
- • Coughing and postnasal drip
- • Presentation of Hay Fever (J32.7): nasal congestion, clear in Hay Fever (J32.7: rhinorrhea, sneezing paroxysms,)
- • Secondary Hay Fever clinical sign: facial sinus pressure, in Hay Fever (J32.7: post-nasal drip, and)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hay Fever Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J32.7 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Allergies, Sinusitis & Immune Reactions | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Total IgE in Hay Fever (J32.7: & Tryptase (if) | Tryptase < 11.4 ng/mL (J32.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Specific IgE Allergen in Hay Fever (J32.7: Panel / Skin) | Targeted trigger identification (J32.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Absolute Eosinophil Count [Hay Fever J32.7] | 0 – 300 cells/uL (J32.7) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hay Fever
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Mometasone Furoate Monohydrate Allergy, Allergy Nasal • RxCUI 1797865 | Corticosteroid | 88% | $1.5635 | $ 12.88 /mo |
| Calmour Childrens Acetaminophen Strips Chewable (Acetaminophen Oral Chewable 80 Mg) Calmour Childrens Acetaminophen Strips Chewable • RxCUI 2705808 | Over-the-Counter Clinical Monograph | 89% | $0.0194 | $ 9.90 /mo |
| Loratadine Allergy Relief, Non Drowsy Allergy Relief • RxCUI 692783 | Allergies Agent | 81% | $0.0393 | $ 5.69 /mo |
| Cold Sore Fever Blister Treatment (Docosanol) Cold Sore Fever Blister Treatment • RxCUI 797534 | Over-the-Counter Clinical Monograph | 94% | $6.6445 | $ 486.90 /mo |
| Fexofenadine HCl Childrens Allergy, Allergy Relief • RxCUI 997491 | Histamine-1 Receptor Antagonist | 82% | $0.1512 | $ 9.05 /mo |
| Cetirizine HCl Allergy Relief, Childrens 24 Hour Allergy • RxCUI 1014675 | Histamine-1 Receptor Antagonist | 90% | $0.0216 | $ 5.45 /mo |
| Fexofenadine Hydrochloride Allergy Relief, Cabinet Allergy Relief Fexofenadine • RxCUI 997420 | Histamine-1 Receptor Antagonist | 79% | $0.2703 | $ 9.05 /mo |
| Allergena Texas Cedar Fever Tabs (Allergy Relief) Allergena Texas Cedar Fever Tabs • RxCUI RXN-B62713956 | Non-Standardized Pollen Allergenic Extract | 87% | $0.0554 | $ 12.49 /mo |
| Diphenhydramine HCl Allergy Relief, Sleep Aid • RxCUI 1049909 | Histamine-1 Receptor Antagonist | 79% | $0.0275 | $ 5.27 /mo |
| Loratadine Oral Claritin • RxCUI 311372 | Allergies Agent | 89% | $0.0393 | $ 5.69 /mo |
| Childrens Pain Reliever (Acetaminophen) Childrens Pain Reliever • RxCUI 307668 | Expectorant | 87% | $0.0194 | $ 9.90 /mo |
| Childrens Pain and Fever (Acetaminophen) Childrens Pain and Fever • RxCUI 307668-B42507148 | Over-the-Counter Clinical Monograph | 74% | $0.0194 | $ 9.90 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hay Fever)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Immunogenicity and safety of concomitant and sequential administration of yellow: What a 900-Participant Study Found In this study, YF-17D vaccine and TAK-003 were immunogenic and well tolerated when sequentially or concomitantly administered. PLoS neglected tropical diseases • 2023-03-15 • Phase III Randomized Trial | N = 900 | 93/100 | PMID 36888687 ↗ |
| Can This Approach Help? Inside the Latest Research on Oral desensitization therapy for peanut allergy induces dynamic changes in Oral desensitization therapy with AR101 leads to decreased basophil sensitivity to peanut and reshapes peanut-reactive T effector cell responses supporting its potential as an immunomodulatory therapy. Allergy • 2022-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35266148 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live No important safety risks were identified, and TAK-003 was well tolerated irrespective of age, gender, or baseline dengue serostatus in recipients aged 4-60 years. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2023-02-08 • Phase III Randomized Trial | N = 14 | 88/100 | PMID 35639602 ↗ |
| Can This Approach Help? Inside the Latest Research on A randomised, gold-standard blind, compared against a dummy pill (placebo) phase Although a primary endpoint was not met in the preceding trial, long-term administration of TCZ showed stable real-world benefits and safety for patients with crFMF. Clinical and experimental rheumatology • 2022-09-15 • Phase III Randomized Trial | N = 23 | 88/100 | PMID 36106542 ↗ |
| New Insights on Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic: What a 318-Participant Study Found Reproxalap was effective at reducing ocular itching in patients with allergic conjunctivitis. American journal of ophthalmology • 2021-10-15 • Phase III Randomized Trial | N = 318 | 87/100 | PMID 33945820 ↗ |
Hay Fever Patient Community & “People Like Me” Threads
Filter Hay Fever community threads and patient logs by age, biological sex, dosage, and treatment duration.